NU 627 Exam 4 | Actual Q&A | 2026 Updated | With Complete Solutions - Herzing University 40-Question Exam
Herzing University — NU 627 Exam 4
Actual Questions and Answers
2026 Updated — With Complete Solutions
Graduate Nursing • Advanced Practice Nursing • Pathophysiology & Pharmacology
40-Question Exam • 4 Sections
Curriculum Alignment: Herzing University NU 627 (Advanced Pathophysiology, Pharmacology, Clinical
Assessment, Complex Disease Management)
Domains: Advanced Endocrine (GLP-1/SGLT2/incretins, thyroid, adrenal) • Renal/GU (AKI, CKD, BPH,
nephrotic/nephritic) • Hematology/Oncology (anemias, coagulopathies, leukemias, lymphomas,
targeted/immunotherapy) • MSK/Integumentary (osteoporosis, RA, gout, bDMARDs, wound care) • 2026 Precision
Medicine, Pharmacogenomics, AI Diagnostics
Sectio
Focus Items
n
1 Advanced Endocrine Disorders & Pharmacology Q1–Q10 (10)
2 Renal and Genitourinary Alterations Q11–Q20 (10)
3 Hematology and Oncology Pathophysiology Q21–Q30 (10)
4 Musculoskeletal, Integumentary & 2026 Clinical Updates Q31–Q40 (10)
Total 40 Items — Cognitive mix: 30% recall, 50% application, 20% analysis 40
Format: 75% scenario-based (complex patient case studies, selecting the appropriate advanced pharmacological
agent, interpreting diagnostic lab trends); 25% direct (pathophysiological mechanisms, pharmacological
classifications). Each item presents four options (A–D), one keyed answer, and a multi-layered rationale identifying
the correct mechanism/pharmacology and the specific flaw in each distractor. Aligned with 2026 ADA/EASD,
KDIGO, NCCN, and ACS guidelines.
Page 1 | NU 627 Exam 4 | 2026 Herzing Edition
,NU 627 Exam 4 | Actual Q&A | 2026 Updated | With Complete Solutions - Herzing University 40-Question Exam
Section 1: Advanced Endocrine Disorders & Pharmacology (Q1–Q10)
1. A 54-year-old with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD) currently
takes metformin and sulfonylurea with an HbA1c of 8.4%. Per 2026 ADA/EASD guidance, which add-on
therapy most directly addresses cardiovascular outcomes (MACE reduction)?
A. Add a thiazolidinedione (pioglitazone) for insulin sensitization.
B. Add an SGLT2 inhibitor (e.g., empagliflozin) or a GLP-1 receptor agonist with proven CV benefit, as
both have demonstrated MACE reduction in this population.
C. Add a sulfonylurea dose increase (glipizide).
D. Add a rapid-acting insulin analog at mealtimes.
Correct Answer: B
Rationale: In T2DM with ASCVD, 2026 ADA/EASD guidelines prioritize SGLT2 inhibitors or GLP-1 RAs with
proven CV benefit for MACE reduction independent of glycemic effect. Pioglitazone (A) has CV data but carries HF
risk; sulfonylurea uptitration (C) and mealtime insulin (D) target glucose, not CV outcomes. B is correct.
2. A 62-year-old with T2DM and heart failure (HFrEF, EF 32%) needs add-on therapy. Which agent is most
appropriate based on 2026 guidelines?
A. A thiazolidinedione (pioglitazone) for insulin sensitization.
B. An SGLT2 inhibitor (e.g., dapagliflozin, empagliflozin), which reduces HF hospitalization and
mortality in HFrEF regardless of diabetes status.
C. A sulfonylurea.
D. A DPP-4 inhibitor (saxagliptin).
Correct Answer: B
Rationale: SGLT2 inhibitors are recommended in HFrEF for HF hospitalization/mortality benefit.
Thiazolidinediones (A) are contraindicated in HF (fluid retention), sulfonylureas (C) do not modify HF outcomes,
and saxagliptin (D) may worsen HF. B is correct.
3. A 47-year-old with obesity (BMI 36) and T2DM (HbA1c 8.1%) is started on semaglutide. Which counseling
point is most accurate regarding mechanism and adverse effects?
A. It works by inhibiting DPP-4 and has minimal GI effects.
B. It is a GLP-1 receptor agonist that slows gastric emptying and increases satiety; common adverse
effects include nausea, vomiting, and diarrhea, with rare pancreatitis and thyroid C-cell tumor concerns
(contraindicated in personal/family history of MTC or MEN2).
C. It primarily reduces renal glucose reabsorption.
D. It stimulates pancreatic alpha cells to release glucagon.
Correct Answer: B
Rationale: Semaglutide is a GLP-1 RA increasing glucose-dependent insulin secretion, slowing gastric emptying, and
increasing satiety; GI effects are common and there are warnings for pancreatitis and thyroid C-cell tumors
(MTC/MEN2 contraindications). DPP-4 inhibition (A) is a different class, SGLT2-style renal action (C) is wrong,
and alpha-cell glucagon stimulation (D) is incorrect. B is correct.
Page 2 | NU 627 Exam 4 | 2026 Herzing Edition
, NU 627 Exam 4 | Actual Q&A | 2026 Updated | With Complete Solutions - Herzing University 40-Question Exam
4. A 2026-era dual/triple incretin agonist (e.g., tirzepatide) combines GLP-1 and GIP receptor agonism. Which
statement best explains its pharmacological advantage?
A. It inhibits SGLT2 in addition to GLP-1, providing renal glucose loss.
B. Dual GIP/GLP-1 receptor agonism produces greater glycemic and weight-loss effects than selective
GLP-1 RAs, via complementary incretin pathways (insulin secretion, satiety, adipose metabolism).
C. It blocks cortisol synthesis to reduce hyperglycemia.
D. It replaces the need for basal insulin in all T1DM patients.
Correct Answer: B
Rationale: Tirzepatide's dual GIP/GLP-1 agonism yields additive glycemic and weight-loss effects via
complementary incretin pathways. It does not inhibit SGLT2 (A), does not affect cortisol (C), and is not indicated for
T1DM (D — incretins require functional beta cells). B is correct.
5. A 38-year-old woman presents with palpitations, heat intolerance, weight loss, and a fine tremor. Labs show
suppressed TSH, elevated free T3 and T4, and positive TSH receptor antibodies. Which pathophysiological
mechanism and pharmacologic first-line therapy are correct?
A. Hashimoto thyroiditis; levothyroxine replacement.
B. Graves disease (TSH receptor-stimulating antibodies causing excess thyroid hormone synthesis);
first-line thionamide antithyroid drug such as methimazole.
C. Subacute thyroiditis; antibiotics.
D. Toxic multinodular goiter; radioactive iodine alone with no thionamide.
Correct Answer: B
Rationale: Suppressed TSH with elevated T3/T4 and TSH receptor-stimulating antibodies is Graves disease;
methimazole (thionamide) inhibits thyroid hormone synthesis and is first-line in many patients. Hashimoto (A) causes
hypothyroidism, subacute thyroiditis (C) is not bacterial, and toxic MNG (D) is treated with RAI but not as first-line
for Graves. B is correct.
6. A patient on methimazole for Graves disease develops fever, sore throat, and oral ulcers. Which lab and
clinical action is most urgent?
A. Continue methimazole and monitor symptoms at home.
B. Stop methimazole immediately, obtain CBC with differential to evaluate for agranulocytosis, and treat
any infection; methimazole-induced agranulocytosis is a medical emergency.
C. Switch to levothyroxine without stopping methimazole.
D. Add a beta-blocker and continue methimazole.
Correct Answer: B
Rationale: Fever and sore throat on methimazole suggest agranulocytosis; the drug must be stopped, CBC obtained,
and infection managed. Continuing (A), adding levothyroxine (C), or beta-blockade alone (D) ignore the
life-threatening complication. B is correct.
7. A 45-year-old presents with hypertension, hypokalemia, metabolic alkalosis, and central obesity, moon
facies, and purple striae. Which set of labs confirms hypercortisolism (Cushing syndrome)?
A. Elevated morning cortisol only.
B. Elevated 24-hour urine free cortisol, loss of cortisol suppression on overnight dexamethasone
suppression test, and elevated late-night salivary cortisol.
C. Suppressed ACTH with low cortisol.
D. Normal 24-hour urine free cortisol with elevated aldosterone.
Correct Answer: B
Page 3 | NU 627 Exam 4 | 2026 Herzing Edition
Herzing University — NU 627 Exam 4
Actual Questions and Answers
2026 Updated — With Complete Solutions
Graduate Nursing • Advanced Practice Nursing • Pathophysiology & Pharmacology
40-Question Exam • 4 Sections
Curriculum Alignment: Herzing University NU 627 (Advanced Pathophysiology, Pharmacology, Clinical
Assessment, Complex Disease Management)
Domains: Advanced Endocrine (GLP-1/SGLT2/incretins, thyroid, adrenal) • Renal/GU (AKI, CKD, BPH,
nephrotic/nephritic) • Hematology/Oncology (anemias, coagulopathies, leukemias, lymphomas,
targeted/immunotherapy) • MSK/Integumentary (osteoporosis, RA, gout, bDMARDs, wound care) • 2026 Precision
Medicine, Pharmacogenomics, AI Diagnostics
Sectio
Focus Items
n
1 Advanced Endocrine Disorders & Pharmacology Q1–Q10 (10)
2 Renal and Genitourinary Alterations Q11–Q20 (10)
3 Hematology and Oncology Pathophysiology Q21–Q30 (10)
4 Musculoskeletal, Integumentary & 2026 Clinical Updates Q31–Q40 (10)
Total 40 Items — Cognitive mix: 30% recall, 50% application, 20% analysis 40
Format: 75% scenario-based (complex patient case studies, selecting the appropriate advanced pharmacological
agent, interpreting diagnostic lab trends); 25% direct (pathophysiological mechanisms, pharmacological
classifications). Each item presents four options (A–D), one keyed answer, and a multi-layered rationale identifying
the correct mechanism/pharmacology and the specific flaw in each distractor. Aligned with 2026 ADA/EASD,
KDIGO, NCCN, and ACS guidelines.
Page 1 | NU 627 Exam 4 | 2026 Herzing Edition
,NU 627 Exam 4 | Actual Q&A | 2026 Updated | With Complete Solutions - Herzing University 40-Question Exam
Section 1: Advanced Endocrine Disorders & Pharmacology (Q1–Q10)
1. A 54-year-old with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD) currently
takes metformin and sulfonylurea with an HbA1c of 8.4%. Per 2026 ADA/EASD guidance, which add-on
therapy most directly addresses cardiovascular outcomes (MACE reduction)?
A. Add a thiazolidinedione (pioglitazone) for insulin sensitization.
B. Add an SGLT2 inhibitor (e.g., empagliflozin) or a GLP-1 receptor agonist with proven CV benefit, as
both have demonstrated MACE reduction in this population.
C. Add a sulfonylurea dose increase (glipizide).
D. Add a rapid-acting insulin analog at mealtimes.
Correct Answer: B
Rationale: In T2DM with ASCVD, 2026 ADA/EASD guidelines prioritize SGLT2 inhibitors or GLP-1 RAs with
proven CV benefit for MACE reduction independent of glycemic effect. Pioglitazone (A) has CV data but carries HF
risk; sulfonylurea uptitration (C) and mealtime insulin (D) target glucose, not CV outcomes. B is correct.
2. A 62-year-old with T2DM and heart failure (HFrEF, EF 32%) needs add-on therapy. Which agent is most
appropriate based on 2026 guidelines?
A. A thiazolidinedione (pioglitazone) for insulin sensitization.
B. An SGLT2 inhibitor (e.g., dapagliflozin, empagliflozin), which reduces HF hospitalization and
mortality in HFrEF regardless of diabetes status.
C. A sulfonylurea.
D. A DPP-4 inhibitor (saxagliptin).
Correct Answer: B
Rationale: SGLT2 inhibitors are recommended in HFrEF for HF hospitalization/mortality benefit.
Thiazolidinediones (A) are contraindicated in HF (fluid retention), sulfonylureas (C) do not modify HF outcomes,
and saxagliptin (D) may worsen HF. B is correct.
3. A 47-year-old with obesity (BMI 36) and T2DM (HbA1c 8.1%) is started on semaglutide. Which counseling
point is most accurate regarding mechanism and adverse effects?
A. It works by inhibiting DPP-4 and has minimal GI effects.
B. It is a GLP-1 receptor agonist that slows gastric emptying and increases satiety; common adverse
effects include nausea, vomiting, and diarrhea, with rare pancreatitis and thyroid C-cell tumor concerns
(contraindicated in personal/family history of MTC or MEN2).
C. It primarily reduces renal glucose reabsorption.
D. It stimulates pancreatic alpha cells to release glucagon.
Correct Answer: B
Rationale: Semaglutide is a GLP-1 RA increasing glucose-dependent insulin secretion, slowing gastric emptying, and
increasing satiety; GI effects are common and there are warnings for pancreatitis and thyroid C-cell tumors
(MTC/MEN2 contraindications). DPP-4 inhibition (A) is a different class, SGLT2-style renal action (C) is wrong,
and alpha-cell glucagon stimulation (D) is incorrect. B is correct.
Page 2 | NU 627 Exam 4 | 2026 Herzing Edition
, NU 627 Exam 4 | Actual Q&A | 2026 Updated | With Complete Solutions - Herzing University 40-Question Exam
4. A 2026-era dual/triple incretin agonist (e.g., tirzepatide) combines GLP-1 and GIP receptor agonism. Which
statement best explains its pharmacological advantage?
A. It inhibits SGLT2 in addition to GLP-1, providing renal glucose loss.
B. Dual GIP/GLP-1 receptor agonism produces greater glycemic and weight-loss effects than selective
GLP-1 RAs, via complementary incretin pathways (insulin secretion, satiety, adipose metabolism).
C. It blocks cortisol synthesis to reduce hyperglycemia.
D. It replaces the need for basal insulin in all T1DM patients.
Correct Answer: B
Rationale: Tirzepatide's dual GIP/GLP-1 agonism yields additive glycemic and weight-loss effects via
complementary incretin pathways. It does not inhibit SGLT2 (A), does not affect cortisol (C), and is not indicated for
T1DM (D — incretins require functional beta cells). B is correct.
5. A 38-year-old woman presents with palpitations, heat intolerance, weight loss, and a fine tremor. Labs show
suppressed TSH, elevated free T3 and T4, and positive TSH receptor antibodies. Which pathophysiological
mechanism and pharmacologic first-line therapy are correct?
A. Hashimoto thyroiditis; levothyroxine replacement.
B. Graves disease (TSH receptor-stimulating antibodies causing excess thyroid hormone synthesis);
first-line thionamide antithyroid drug such as methimazole.
C. Subacute thyroiditis; antibiotics.
D. Toxic multinodular goiter; radioactive iodine alone with no thionamide.
Correct Answer: B
Rationale: Suppressed TSH with elevated T3/T4 and TSH receptor-stimulating antibodies is Graves disease;
methimazole (thionamide) inhibits thyroid hormone synthesis and is first-line in many patients. Hashimoto (A) causes
hypothyroidism, subacute thyroiditis (C) is not bacterial, and toxic MNG (D) is treated with RAI but not as first-line
for Graves. B is correct.
6. A patient on methimazole for Graves disease develops fever, sore throat, and oral ulcers. Which lab and
clinical action is most urgent?
A. Continue methimazole and monitor symptoms at home.
B. Stop methimazole immediately, obtain CBC with differential to evaluate for agranulocytosis, and treat
any infection; methimazole-induced agranulocytosis is a medical emergency.
C. Switch to levothyroxine without stopping methimazole.
D. Add a beta-blocker and continue methimazole.
Correct Answer: B
Rationale: Fever and sore throat on methimazole suggest agranulocytosis; the drug must be stopped, CBC obtained,
and infection managed. Continuing (A), adding levothyroxine (C), or beta-blockade alone (D) ignore the
life-threatening complication. B is correct.
7. A 45-year-old presents with hypertension, hypokalemia, metabolic alkalosis, and central obesity, moon
facies, and purple striae. Which set of labs confirms hypercortisolism (Cushing syndrome)?
A. Elevated morning cortisol only.
B. Elevated 24-hour urine free cortisol, loss of cortisol suppression on overnight dexamethasone
suppression test, and elevated late-night salivary cortisol.
C. Suppressed ACTH with low cortisol.
D. Normal 24-hour urine free cortisol with elevated aldosterone.
Correct Answer: B
Page 3 | NU 627 Exam 4 | 2026 Herzing Edition
